Preetam Shah
2022
In 2022, Preetam Shah earned a total compensation of $683.7K as Chief Financial Officer and Chief Business Officer at Cidara Therapeutics.
Compensation breakdown
| Non-Equity Incentive Plan | $151,300 |
|---|---|
| Option Awards | $54,028 |
| Salary | $417,400 |
| Stock Awards | $51,836 |
| Other | $9,150 |
| Total | $683,714 |
Shah received $417.4K in salary, accounting for 61% of the total pay in 2022.
Shah also received $151.3K in non-equity incentive plan, $54K in option awards, $51.8K in stock awards and $9.2K in other compensation.
Rankings
In 2022, Preetam Shah's compensation ranked 3,824th out of 5,760 executives tracked by ExecPay. In other words, Shah earned more than 33.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,824 out of 5,760 | 34th |
Division Manufacturing | 2,162 out of 3,136 | 31st |
Major group Chemicals And Allied Products | 1,043 out of 1,422 | 27th |
Industry group Drugs | 979 out of 1,323 | 26th |
Industry Biological Products, Except Diagnostic Substances | 229 out of 291 | 21st |
Source: SEC filing on April 27, 2023.
Shah's colleagues
We found two more compensation records of executives who worked with Preetam Shah at Cidara Therapeutics in 2022.